Samuel Katsuyuki Shinjo
A5032728136- Inflammatory Myopathies and Dermatomyositis
- Vasculitis and related conditions
- Eosinophilic Disorders and Syndromes
- Systemic Sclerosis and Related Diseases
- Skin Diseases and Diabetes
- Systemic Lupus Erythematosus Research
- Muscle Physiology and Disorders
- Peripheral Neuropathies and Disorders
- Parkinson's Disease and Spinal Disorders
- Immunodeficiency and Autoimmune Disorders
- SARS-CoV-2 and COVID-19 Research
- Muscle and Compartmental Disorders
- Fibromyalgia and Chronic Fatigue Syndrome Research
- COVID-19 Clinical Research Studies
- Otitis Media and Relapsing Polychondritis
- Neurogenetic and Muscular Disorders Research
- Rheumatoid Arthritis Research and Therapies
- Long-Term Effects of COVID-19
- Transcranial Magnetic Stimulation Studies
- Autoimmune and Inflammatory Disorders Research
- Dermatological and Skeletal Disorders
- Chronic Lymphocytic Leukemia Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Celiac Disease Research and Management
- Dermatological and COVID-19 studies
Universidade de São Paulo
2016-2025
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2015-2025
University Center of Brasília
2022-2023
Covance (United States)
2023
CSL (Switzerland)
2023
University of Pittsburgh
2023
Merck (Germany)
2023
Galapagos (Belgium)
2023
Janssen (Switzerland)
2023
Janssen (Belgium)
2023
Cardiac troponin (cTn) T and cTnI are considered cardiac specific equivalent in the diagnosis of acute myocardial infarction. Previous studies suggested rare skeletal myopathies as a noncardiac source cTnT. We aimed to confirm reliability/cardiac specificity cTnT patients with various muscle disorders (SMDs).We prospectively enrolled presenting muscular complaints (≥2 weeks) for elective evaluation 4 hospitals 2 countries. After workup, were adjudicated into 3 predefined disease categories....
To evaluate the beneficial effect of antimalarial treatment on lupus survival in a large, multiethnic, international longitudinal inception cohort.Socioeconomic and demographic characteristics, clinical manifestations, classification criteria, laboratory findings, variables were examined patients with systemic erythematosus (SLE) from Grupo Latino Americano de Estudio del Lupus Eritematoso (GLADEL) cohort. The diagnosis SLE, according to American College Rheumatology was assessed within 2...
OBJECTIVE:To analyze the prevalence of myositis-specific and myositis-associated autoantibodies their clinical correlations in a large series patients with dermatomyositis/polymyositis.METHOD: This cross-sectional study enrolled 127 dermatomyositis cases 95 polymyositis cases.The diseaserelated autoantibody profiles were determined using commercially available blood testing kit.RESULTS: The all 222 was 34.4%, whereas myositisassociated found 41.4% patients.The most frequently anti-Ro-52...
Abstract Introduction Our aim was to evaluate the safety and efficacy of a low-intensity resistance training program combined with partial blow flow restriction (BFR training) in cohort patients polymyositis (PM) dermatomyositis (DM). Methods In total, 13 PM DM completed 12-week twice week (that is, 30% one-repetition-maximum (1RM)) exercise blood (BFR). Assessments muscle strength, physical function, quadriceps cross sectional (CSA) area, health-related quality life, clinical laboratory...
Abstract Background Strength and muscle mass are predictors of relevant clinical outcomes in critically ill patients, but hospitalized patients with COVID‐19, it remains to be determined. In this prospective observational study, we investigated whether strength or predictive hospital length stay (LOS) moderate severe COVID‐19 patients. Methods We evaluated prospectively 196 at admission for strength. Ten did not test positive SARS‐CoV‐2 during hospitalization were excluded from the analyses....
Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy manage pandemic. Although none of currently approved vaccines are live-attenuated, several reports disease flares, waning protection, acute-onset syndromes emerged as short-term adverse events after...
Objective To determine the immunogenicity of third dose CoronaVac vaccine in a large population patients with autoimmune rheumatic diseases (ARD) and factors associated impaired response. Methods Adult ARD age-balanced/sex-balanced controls (control group, CG) previously vaccinated two doses received at D210 (6 months after second dose). The presence anti-SARS-CoV-2 S1/S2 IgG neutralising antibodies (NAb) was evaluated to vaccination (D210) 30 days later (D240). Patients controlled disease...
Abstract Introduction/Aims In this study we investigated COVID‐19 vaccination–related adverse events (ADEs) 7 days postvaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune disorders (SAIDs). Methods Seven‐day vaccine ADEs were collected an international patient self‐reported e‐survey. Descriptive statistics obtained multivariable regression was performed. Results Ten thousand nine hundred respondents analyzed (1227 IIM cases, 4640 SAID 5033...
ABSTRACT Objectives To determine the prevalence of self‐reported delayed adverse events (DAEs), major AEs, and flares following COVID‐19 vaccinations among patients with autoimmune rheumatic diseases (AIRDs) in Malaysia. Methodology An electronically validated survey from vaccination (COVAD) study group was distributed July 2021 to healthy controls (HCs). The collected data on DAEs (any AE that persisted or occurred after 7 days vaccination), any early (MAEs), vaccination. Generalized...
Abstract Objectives To comprehensively compare the disease burden among patients with RA, PsA and AS using Patient-Reported Outcome Measurement Information System (PROMIS) scores to identify distinct patient clusters based on comorbidity profiles PROMIS outcomes. Methods Data from global COVID-19 Vaccination in Autoimmune Diseases (COVAD) 2 e-survey were analysed. Patients or undergoing treatment DMARDs included. (global physical health, mental fatigue 4a function short form 10a),...
Background Despite the WHO recommendation that 2010–2011 trivalent seasonal flu vaccine must contain A/California/7/2009/H1N1-like virus there is no consistent data regarding its immunogenicity and safety in a large autoimmune rheumatic disease (ARD) population. Methods 1668 ARD patients (systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic sclerosis, psoriatic (PsA), Behçet's (BD), mixed connective tissue disease, primary antiphospholipid...
The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution reducing poor clinical outcomes, vaccine hesitancy an obstacle achieving high levels uptake. This represents particular risk patients with autoimmune diseases, group already at increased hospitalization outcomes related infection. there is paucity long-term safety efficacy data in current evidence...
We compared outcomes of alveolar hemorrhage (AH) in juvenile (JSLE) and adult onset SLE (ASLE). From 263 JSLE 1522 ASLE, the AH occurred 13 (4.9%) 15 (1.0%) patients, respectively ( p < .001). Both groups had comparable disease duration (2.6 ± 3.0 vs. 5.6 7.0 years, = .151) median SLEDAI scores [17.5 (2 to 32) 17.5 (3 28), 1.000]. At onset, a higher frequency were already on high prednisone dose > 0.5 mg/kg/day) ASLE (54% 15%, .042). The mean drop hemoglobin was significantly lower...
Abstract Objective To evaluate the frequency of metabolic syndrome in dermatomyositis (DM) patients and to analyze possible association with traditional cardiovascular disease (CVD) risk factors DM‐related clinical laboratory features. Methods The present cross‐sectional single‐center study included 84 DM 105 healthy controls. Metabolic was diagnosed according National Cholesterol Education Program Adult Treatment Panel III. Results median age similar both control groups (41.5 42.0 years,...
Abstract Objectives COVID-19 vaccines have been proven to be safe in the healthy population. However, gaps remain evidence of their safety patients with systemic autoimmune and inflammatory disorders (SAIDs). vaccination-related adverse events (AEs) SAIDs controls (HC) seven days post-vaccination were assessed COVAD study, a patient self-reported cross-sectional survey. Methods The survey was circulated early 2021 by &gt;110 collaborators (94 countries) collect SAID details, vaccination...
COVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs); however, hesitancy continues to persist among these patients. Therefore, we studied the prevalence, predictors and reasons for IIMs, other AIRDs, non-rheumatic (nrAIDs) healthy controls (HCs), using data from two international Vaccination Autoimmune Diseases (COVAD) e-surveys.The first second COVAD patient self-reported e-surveys were...
Abstract Objective Flares of autoimmune rheumatic diseases (AIRDs) following COVID-19 vaccination are a particular concern in vaccine-hesitant individuals. Therefore, we investigated the incidence, predictors and patterns flares individuals living with AIRDs, using global Vaccination Autoimmune Diseases (COVAD) surveys. Methods The COVAD surveys were used to extract data on flare demographics, comorbidities, history, details for patients AIRDs. identified as patient-reported (a), increased...